Login to Your Account

Tetraphase Lands $67M BARDA Contract for Antibiotic TP-434

By Trista Morrison
Staff Writer

Friday, February 17, 2012
Less than six months after winning a $36 million National Institutes of Health (NIH) contract for respiratory antibiotic TP-271, Tetraphase Pharmaceuticals Inc. landed a $67 million BARDA contract for broad-spectrum antibiotic TP-434.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription